Lupin Limited, a key player in the global pharmaceutical landscape, has declared that it obtained the green light from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). This milestone covers the production of […]
Lupin Secures US FDA Nod for Generic Version of Extended-Release Adderall XR Capsules Read More »
India’s medical tourism industry is rapidly expanding, establishing the nation as a premier global hub for cost-effective and superior healthcare solutions. The country’s reputation is bolstered by healthcare facilities like PSRI Hospital, which excel in patient-focused, clinical care, affirming India’s
The Telangana government has proudly reported remarkable strides in the life sciences domain, amassing investments exceeding Rs. 36,000 crore across more than 140 projects within the past year. These investments are projected to generate 51,000 direct employment opportunities and approximately
Anixa Biosciences, Inc. (Anixa), a biotech firm dedicated to cancer treatment and prevention, revealed its initiation of patient treatment in the third cohort of its ongoing Phase 1 clinical trial. This trial explores their innovative chimeric antigen receptor-T cell (CAR-T)
Scientists at the National Institutes of Health (NIH) have engineered an innovative artificial intelligence (AI) system aimed at optimizing the matching of prospective trial participants with appropriate clinical research studies listed on ClinicalTrials.gov. A paper in Nature Communications highlights the
AI System by NIH Enhances Patient Matching for Clinical Trials Read More »
TAHO Pharmaceuticals Ltd. has begun administering doses to participants in its phase III trial in the US for its leading product, TAH3311, a pioneering antithrombotic oral dissolving film (ODF). In July 2023, their proposal for a 505(b)(2) NDA submission, which
TAHO Pharma Initiates Dosing in US Phase III Study of Antithrombotic Oral Film, TAH3311 Read More »
Cytokinetics, a specialty biopharmaceutical company focusing on cardiovascular diseases in advanced stages, has joined forces with Bayer through an exclusive collaboration and licensing arrangement. This partnership aims to advance the development and marketing of aficamten for patients in Japan suffering
Cytokinetics and Bayer Partner for Aficamten Development and Commercialization in Japan Read More »
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the drug sparsentan, also known as Filspari, for the treatment of primary immunoglobulin A nephropathy (IgAN). Renowned as IgA nephropathy or Berger’s disease, this kidney disorder arises
UK MHRA Approves Sparsentan for Treating Primary IgA Nephropathy in Adults Read More »
Abbott, a leader in the healthcare sector, revealed significant new findings concerning its Amplatzer Amulet Left Atrial Appendage (LAA) Occluder for individuals with atrial fibrillation (AFib) who face heightened stroke risk. Recent five-year research highlights that patients using Abbott’s Amplatzer
Biosion, Inc. (Biosion), a global biotechnology company in the R&D phase, unveiled a new exclusive licensing deal with Aclaris Therapeutics. This agreement grants Biosion universal rights (excluding Greater China) for BSI-045B, a potential pioneering, clinical-stage, innovative anti-TSLP monoclonal antibody, in